FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011296007> ?p ?o ?g. }

• W2011296007 endingPage "196" @default.
• W2011296007 startingPage "191" @default.
• W2011296007 abstract "To assess the efficacy and safety of infliximab in the treatment of sight-threatening uveitis and extraocular manifestations in patients with Behçet's disease. Twelve patients with Behçet's disease and uveitis were treated with infliximab after unsuccessful therapy with other immunosuppressive drugs. The main outcome measures were as follows: the number of uveitis relapses, the number of Behçet's disease-related extraocular lesions, and the amount of corticosteroids administered during the treatment as well as during an equal prior period of time while the patients were on other immunosuppressive agents. Visual acuity was recorded at the beginning of infliximab therapy and at the end of follow-up, and was defined as stable if it did not change from baseline, increased if it showed at least one line of improvement from baseline, and decreased if it showed at least a one line decrease from baseline. During an average follow-up of 16.67 ± 7.63 months (median, 15 months), 11 patients (91.6%) showed a reduction in the number of ocular relapses (relapse/month, from 0.35 ± 0.17 to 0.12 ± 0.17, P < 0.001). All of the patients (n = 11) who were taking corticosteroids before infliximab were able to reduce the amount of corticosteroids taken daily during infliximab treatment (from 24.33 ± 10.84 mg/prednisone per day to 8.97 ± 6.81 mg/prednisone per day, P < 0.001), and all presented with a reduced onset of extraocular manifestations of Behçet's disease (mean total number, from 2.83 ± 3.61 to 1.51 ± 2.35, P = 0.039). One patient, who had to stop treatment 2 months after starting because of the onset of pulmonary tuberculosis, showed the same number of relapses during infliximab treatment but was able to reduce the mean daily corticosteroid dose. Visual acuity increased by one or more lines in three eyes (12.5%) and remained unchanged in 87.5% of the eyes. Infliximab-related side effects appeared in four patients (33.3%). Infliximab was effective in the treatment of uveitis in these Behçet's disease patients, significantly reducing the number of ocular relapses and making possible a significant reduction in the daily dose of corticosteroids administered. Extraocular manifestations of Behçet's disease were also controlled by infliximab. Nevertheless, side effects were not uncommon, and an extensive study of systemic conditions before infliximab administration had to be carried out to exclude systemic infection, particularly prior tuberculosis. Jpn J Ophthalmol 2007;51:191–196 © Japanese Ophthalmological Society 2007" @default.
• W2011296007 created "2016-06-24" @default.
• W2011296007 creator A5008449155 @default.
• W2011296007 creator A5031734844 @default.
• W2011296007 creator A5051526168 @default.
• W2011296007 creator A5073139082 @default.
• W2011296007 creator A5085128033 @default.
• W2011296007 creator A5089094034 @default.
• W2011296007 date "2007-06-07" @default.
• W2011296007 modified "2023-09-25" @default.
• W2011296007 title "Infliximab Treatment for Ocular and Extraocular Manifestations of Behçet's Disease" @default.
• W2011296007 cites W1994056390 @default.
• W2011296007 cites W2002488023 @default.
• W2011296007 cites W2008597795 @default.
• W2011296007 cites W2009468862 @default.
• W2011296007 cites W2009811989 @default.
• W2011296007 cites W2011959542 @default.
• W2011296007 cites W2016298385 @default.
• W2011296007 cites W2025521578 @default.
• W2011296007 cites W2029087081 @default.
• W2011296007 cites W2036131677 @default.
• W2011296007 cites W2038535814 @default.
• W2011296007 cites W2049056531 @default.
• W2011296007 cites W205584899 @default.
• W2011296007 cites W2065541718 @default.
• W2011296007 cites W2072643599 @default.
• W2011296007 cites W2076064330 @default.
• W2011296007 cites W2101951838 @default.
• W2011296007 cites W2114081005 @default.
• W2011296007 cites W2130228547 @default.
• W2011296007 cites W2130857098 @default.
• W2011296007 cites W2142273705 @default.
• W2011296007 cites W2147171610 @default.
• W2011296007 cites W2152245204 @default.
• W2011296007 cites W2155987419 @default.
• W2011296007 cites W2156195056 @default.
• W2011296007 cites W2158286914 @default.
• W2011296007 cites W2161446589 @default.
• W2011296007 cites W2170726975 @default.
• W2011296007 cites W2319957449 @default.
• W2011296007 cites W2321453230 @default.
• W2011296007 cites W2404444784 @default.
• W2011296007 cites W2414735972 @default.
• W2011296007 cites W2415886096 @default.
• W2011296007 cites W4240560347 @default.
• W2011296007 cites W4300492363 @default.
• W2011296007 cites W4313347683 @default.
• W2011296007 doi "https://doi.org/10.1007/s10384-006-0425-y" @default.
• W2011296007 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17554481" @default.
• W2011296007 hasPublicationYear "2007" @default.
• W2011296007 type Work @default.
• W2011296007 sameAs 2011296007 @default.
• W2011296007 citedByCount "104" @default.
• W2011296007 countsByYear W20112960072012 @default.
• W2011296007 countsByYear W20112960072013 @default.
• W2011296007 countsByYear W20112960072014 @default.
• W2011296007 countsByYear W20112960072015 @default.
• W2011296007 countsByYear W20112960072016 @default.
• W2011296007 countsByYear W20112960072017 @default.
• W2011296007 countsByYear W20112960072018 @default.
• W2011296007 countsByYear W20112960072019 @default.
• W2011296007 countsByYear W20112960072020 @default.
• W2011296007 countsByYear W20112960072021 @default.
• W2011296007 countsByYear W20112960072022 @default.
• W2011296007 countsByYear W20112960072023 @default.
• W2011296007 crossrefType "journal-article" @default.
• W2011296007 hasAuthorship W2011296007A5008449155 @default.
• W2011296007 hasAuthorship W2011296007A5031734844 @default.
• W2011296007 hasAuthorship W2011296007A5051526168 @default.
• W2011296007 hasAuthorship W2011296007A5073139082 @default.
• W2011296007 hasAuthorship W2011296007A5085128033 @default.
• W2011296007 hasAuthorship W2011296007A5089094034 @default.
• W2011296007 hasConcept C118487528 @default.
• W2011296007 hasConcept C126322002 @default.
• W2011296007 hasConcept C141071460 @default.
• W2011296007 hasConcept C2776148792 @default.
• W2011296007 hasConcept C2776194053 @default.
• W2011296007 hasConcept C2777138892 @default.
• W2011296007 hasConcept C2778257484 @default.
• W2011296007 hasConcept C2778720950 @default.
• W2011296007 hasConcept C2779134260 @default.
• W2011296007 hasConcept C2781428731 @default.
• W2011296007 hasConcept C71924100 @default.
• W2011296007 hasConceptScore W2011296007C118487528 @default.
• W2011296007 hasConceptScore W2011296007C126322002 @default.
• W2011296007 hasConceptScore W2011296007C141071460 @default.
• W2011296007 hasConceptScore W2011296007C2776148792 @default.
• W2011296007 hasConceptScore W2011296007C2776194053 @default.
• W2011296007 hasConceptScore W2011296007C2777138892 @default.
• W2011296007 hasConceptScore W2011296007C2778257484 @default.
• W2011296007 hasConceptScore W2011296007C2778720950 @default.
• W2011296007 hasConceptScore W2011296007C2779134260 @default.
• W2011296007 hasConceptScore W2011296007C2781428731 @default.
• W2011296007 hasConceptScore W2011296007C71924100 @default.
• W2011296007 hasIssue "3" @default.
• W2011296007 hasLocation W20112960071 @default.
• W2011296007 hasLocation W20112960072 @default.
• W2011296007 hasOpenAccess W2011296007 @default.

• next